Bionano develops genomic technologies designed to help clinicians and researchers better understand genetic variation and its role in disease. Its central offering is optical genome mapping (OGM), which provides genome-wide detection of structural variants, including changes that may be difficult to resolve with traditional cytogenetic methods or sequencing alone. The company serves clinical care, research and therapeutics, with applications spanning oncology, genetic disease, cytogenomics, molecular genomics and cell bioprocessing.

Bionano’s product portfolio includes the Stratys and Saphyr OGM systems, sample preparation kits, compute solutions and VIA analysis software. VIA combines OGM results with next-generation sequencing, microarray and other data to support genomic interpretation. The Ionic purification system and kits use isotachophoresis to isolate and prepare genomic DNA and RNA from cells, tissue and FFPE samples. Bionano also provides OGM data services through its laboratories and certified service providers, alongside software, training and technical support. The company aims to equip users with more comprehensive genomic insights that can inform disease research and patient care.